ddn Online

The Blog of Drug Discovery News

Up next: Academia’s role in cancer research

If you’re a regular reader of ddn, you’ve probably read the first couple installments of our current series, Trends in Cancer Research, and now the October issue will bring you a focus on the growing importance and role of companion diagnostics in oncology drug pipelines and revenues.

In November, we will be examining academia’s growing role in cancer research as the effort to find new drug candidates to fight this insidious disease continues. We will examine which academic research centers are at the forefront of cancer research; some of the more significant advances in cancer research that came from the academic world; and their main focus in the expansive universe of oncology reseach, be it tumors, delivery, genomics or some other area.

As I cover these areas, another subject I hope to learn more about is whether studying at one of these centers can unlock more career opportunities for its students.

Lastly, we will be asking people how academic research centers select commercial partners—an important issue, of course, with ddn’s business focus.

I welcome input from ddn readers on this vast topic, as many of you are experts in this very area, work in academia in key leadership positions, or know people who have the insights we need for the articles. We have our sources, but we can’t know everyone, and if you can help expand our network, please do. To participate as a source for our upcoming installment or to suggest a source you think I should contact, e-mail me at hutton@drugdiscoverynews.com.

October 11, 2010 Posted by | Academia & Non-Profit, Labwork & Science | , , , , , | Leave a comment